Curated News
By: NewsRamp Editorial Staff
October 07, 2026
VERAXA Biotech Advances FDA-Aligned NAMs to Cut Animal Testing
TLDR
- VERAXA's NAM strategy could accelerate clinical advancement and reduce costs, giving it a competitive edge in antibody-based cancer therapies.
- VERAXA uses FDA-aligned New Approach Methodologies to de-risk its pipeline, evaluating BiTAC and bsADC candidates with ex vivo patient-derived xenograft models.
- VERAXA's NAM approach significantly reduces animal testing, making tomorrow better by advancing cancer therapies with less animal suffering.
- VERAXA's NAM panel required only about 10 mice, compared to 200 or more for traditional in vivo efficacy studies.
Impact - Why it Matters
This news matters because it signals a significant shift in preclinical drug development toward more ethical, efficient, and human-relevant methods. By adopting FDA-aligned NAMs, VERAXA Biotech is not only reducing animal testing—a major ethical and cost concern—but also potentially accelerating the delivery of innovative cancer therapies to patients. The ability to evaluate drug candidates using patient-derived models with far fewer animals could streamline the R&D process, leading to faster clinical trials and lower drug development costs. For investors, this demonstrates VERAXA's commitment to cutting-edge science and operational efficiency, which could enhance its competitive edge in the lucrative oncology market. Ultimately, patients may benefit from quicker access to next-generation antibody-based treatments that are more likely to succeed in clinical trials due to improved preclinical predictability.
Summary
VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced a strategic update on its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. This approach is designed to accelerate clinical advancement, reduce development costs and timelines, and significantly decrease reliance on animal testing. VERAXA has assembled a comprehensive panel of NAMs to characterize and de-risk its pipeline, which includes BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs).
In a key demonstration of its NAM strategy, VERAXA evaluated its lead BiTAC-TCE and bsADC candidates using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. Impressively, this panel required only about 10 mice in total, compared to an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and showcasing how NAMs can reduce animal use and preclinical cycle time without compromising clinical relevance.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, powered by transformative technologies and guided by rigorous quality-by-design principles. BiTAC® is a registered trademark of VERAXA Biotech GmbH. For more information, the full press release is available at https://ibn.fm/9YRJw, and the latest updates relating to VRXA can be found in the company’s newsroom at http://ibn.fm/VRXA. This news is disseminated through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, which is part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech Advances FDA-Aligned NAMs to Cut Animal Testing
